James Parks, MD
Cardiovascular Disease · Birmingham, ALNPI 1255305470
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.0% of the total across 677 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations.
Across 677 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Medtronic$1K
- Abbott$1K
- Amgen$963
- Johnson & Johnson$767
- Merck$738
- plus $7K from 42 others
What the payments were for
- Travel & lodging$1,2349%
- Food & beverage$12,79491%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,045
- Watchman$427
- SAPIEN 3 Ultra RESILIA$154
- JETI$130
- Perclose ProStyle$130
- PERCLOSE PROGLIDE$123
- Perclose ProGlide suture mediated closure system$121
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$121
- TACHOSIL$120
- Supera peripheral stent system$120
- WATCHMAN Access System$117
- Xience Sierra Coronary Stent System$116
- Reveal LINQ$104
How this compares
$14,053 in reported general payments places this provider in the 85th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 891 | $704,032 |
| EntrestoSacubitril/Valsartan | 469 | $379,089 |
| XareltoRivaroxaban | 143 | $132,631 |
| Repatha SureclickEvolocumab | 160 | $111,787 |
| BrilintaTicagrelor | 65 | $45,143 |
| MultaqDronedarone Hcl | 44 | $43,910 |
| JardianceEmpagliflozin | 36 | $32,729 |
| Clonidine | 239 | $32,310 |
| FarxigaDapagliflozin Propanediol | 51 | $28,860 |
| Repatha SyringeEvolocumab | 30 | $23,669 |
| Metoprolol Succinate | 1,289 | $22,727 |
| Atorvastatin Calcium | 700 | $10,736 |
| Nitroglycerin PatchNitroglycerin | 182 | $8,975 |
| ClopidogrelClopidogrel Bisulfate | 731 | $8,971 |
| Losartan Potassium | 608 | $7,594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $645 | $704,032891 claims |
| NovartisEntresto | $2,123 | $379,089469 claims |
| Johnson & JohnsonXarelto | $767 | $132,631143 claims |
| AstraZenecaBrilinta, Farxiga | $546 | $74,003116 claims |
| Sanofi-aventis U.S. LLCMultaq | $358 | $43,91044 claims |
| Boehringer IngelheimJardiance | $561 | $32,72936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Birmingham
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
- Thomas CawthonBirmingham$54K
- Weihan ChenBirmingham$51K
- Farrell MendelsohnBirmingham$51K
- Charles MooreBirmingham$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.